Evidence map›Paper›PMID 26099530›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2015

Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol-Mediated Induction of ΔFosB in the Mouse Forebrain.

Matthew F Lazenka, Aaron J Tomarchio, Aron H Lichtman, Paul Greengard, Marc Flajolet, Dana E Selley, Laura J Sim-Selley

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Tetrahydrocannabinol and dopamine D1 receptor.Frontiers in neuroscience · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. ΔCannabis and cannabinoid research · 2017
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Matthew F LazenkaDepartment of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (M.F.L., A.J.T., A.H.L., D.E.S., L.J.S.-S.); and Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, New York (P.G., M.F.).
Aaron J TomarchioDepartment of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (M.F.L., A.J.T., A.H.L., D.E.S., L.J.S.-S.); and Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, New York (P.G., M.F.).
Aron H LichtmanDepartment of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (M.F.L., A.J.T., A.H.L., D.E.S., L.J.S.-S.); and Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, New York (P.G., M.F.).
Paul GreengardDepartment of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (M.F.L., A.J.T., A.H.L., D.E.S., L.J.S.-S.); and Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, New York (P.G., M.F.).
Marc FlajoletDepartment of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (M.F.L., A.J.T., A.H.L., D.E.S., L.J.S.-S.); and Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, New York (P.G., M.F.).
Dana E SelleyDepartment of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (M.F.L., A.J.T., A.H.L., D.E.S., L.J.S.-S.); and Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, New York (P.G., M.F.).
Laura J Sim-SelleyDepartment of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (M.F.L., A.J.T., A.H.L., D.E.S., L.J.S.-S.); and Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, New York (P.G., M.F.) ljsimsel@vcu.edu.
Rockefeller University · USVirginia Commonwealth University · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Paula Daniela Bos · 1985 to 2026
$51.0M
THE ROLE OF DARPPS IN THE ACUTE AND CHRONIC EFFECTS OF COCAINE AND AMPHETAMINEP01DA010044 · NIDA · ROCKEFELLER UNIVERSITY · PI GREENGARD, PAUL · 1996 to 2015
$23.6M
TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ARON H LICHTMAN · 2014 to 2026
$13.8M
VCU Neuroscience Center Core GrantP30NS047463 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI POVLISHOCK, JOHN T · 2003 to 2013
$5.0M
Endocannabinoid modulation of pain-depressed behaviorR01DA030404 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S, SIM-SELLEY, LAURA J · 2011 to 2020
$3.7M
Neurobiology and Treatment of PainR01NS070715 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S, SELLEY, DANA E · 2009 to 2018
$3.3M
Regulation of striatal cannabinoid CB1 receptors by DARPP32 and deltaFosB mediateF31DA030227 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI LAZENKA, MATTHEW F · 2011 to 2012
$67k
NCI NIH HHS P30 CA016059NCI NIH HHS P30-CA016059NIDA NIH HHS F31 DA030227NIDA NIH HHS F31-DA030227NIDA NIH HHS P01 DA010044NIDA NIH HHS P01-DA10044NIDA NIH HHS P30 DA033934NIDA NIH HHS R01 DA030404NIDA NIH HHS R01-DA030404,NIDA NIH HHS T32 DA007027NINDS NIH HHS P30 NS047463NINDS NIH HHS P30-NS047463NINDS NIH HHS R01 NS070715NINDS NIH HHS R01-NS070715
6 · The paper itself

Abstract

Δ(9)-Tetrahydrocannabinol (THC), the main psychoactive component of marijuana, produces motor and motivational effects via interactions with the dopaminergic system in the caudate-putamen and nucleus accumbens. However, the molecular events that underlie these interactions after THC treatment are not well understood. Our study shows that pretreatment with dopamine D1 receptor (D1R) antagonists before repeated administration of THC attenuated induction of Δ FBJ murine osteosarcoma viral oncogene homolog B (ΔFosB) in the nucleus accumbens, caudate-putamen, amygdala, and prefrontal cortex. Anatomical studies showed that repeated THC administration induced ΔFosB in D1R-containing striatal neurons. Dopamine signaling in the striatum involves phosphorylation-specific effects of the dopamine- and cAMP-regulated phosphoprotein Mr 32 kDa (DARPP-32), which regulates protein kinase A signaling. Genetic deletion of DARPP-32 attenuated ΔFosB expression measured after acute, but not repeated, THC administration in both the caudate-putamen and nucleus accumbens. THC was then acutely or repeatedly administered to wild-type (WT) and DARPP-32 knockout (KO) mice, and in vivo responses were measured. DARPP-32 KO mice exhibited enhanced acute THC-mediated hypolocomotion and developed greater tolerance to this response relative to the WT mice. Agonist-stimulated guanosine 5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTPγS) binding showed that cannabinoid-stimulated G-protein activity did not differ between DARPP-32 KO and WT mice treated with vehicle or repeated THC. These results indicate that D1Rs play a major role in THC-mediated ΔFosB induction in the forebrain, whereas the role of DARPP-32 in THC-mediated ΔFosB induction and modulation of motor activity appears to be more complex.

Indexed as

AmygdalaAnimalsDopamineDopamine and cAMP-Regulated Phosphoprotein 32Dopamine AntagonistsDronabinolLocomotionMaleMiceMice, Inbred C57BLMice, Inbred ICRMice, KnockoutNucleus AccumbensPrefrontal CortexProsencephalonProto-Oncogene Proteins c-fosDopamineDopamine and cAMP-Regulated Phosphoprotein 32Dopamine AntagonistsDronabinolFosb protein, mousePpp1r1b protein, mouseProto-Oncogene Proteins c-fosReceptors, Dopamine D1

Identifiers

PMID26099530
PMCPMC4538878
OpenAlexW1963354650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.